Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with irreversible
loss of lung tissue and function. Myofibroblasts in the lung are key cellular mediators of IPF …

Transforming growth factor (TGF)-β1, a main profibrogenic cytokine in the progression of
idiopathic pulmonary fibrosis (IPF), induces differentiation of pulmonary fibroblasts to …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal fibrotic lung disease
characterized by profound changes in stem cell differentiation, epithelial cell phenotypes …

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease. The pathogenesis of
IPF is not completely understood. However, numerous genes are associated with the …

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic lung disease with an
undefined etiology and no effective treatments. By binding to cell surface receptors …

Idiopathic pulmonary fibrosis (IPF) is a progressive terminal lung disease, and therapies aim
to block fibrosis. Fibroblast proliferation is controlled by C/EBP-β, microRNA cluster 17-92 …

Idiopathic pulmonary fibrosis (IPF) is a fatal disorder resulting from the progressive
remodeling of lungs, with no known effective treatment. Although transforming growth factor …

Although microRNA (miRNA) dysregulation with intracellular signaling cascade disruption
has been demonstrated in the pathophysiology of pulmonary fibrosis, the relationship …

Idiopathic pulmonary fibrosis (IPF) is a serious lung disease that involved the myofibroblast
differentiation of lung resident mesenchymal stem cells (LR-MSCs). However, the specific …

Idiopathic pulmonary fibrosis (IPF) is one of the most common and severe interstitial lung
diseases. Epithelial-to-mesenchymal transition (EMT) is a process whereby epithelial cells …